Study of efficacy and adverse effect of fluticasone and formoterol combination in bronchial asthma
Keywords:Fluticasone/Formoterol, Forced expiratory volume in the first second, Bronchial asthma
Background: Bronchial asthma is a chronic inflammatory disorder of the airways associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing particularly at night or in the early morning.
Methods: This study has recruited 25 newly (male/female) cases of Bronchial Asthma diagnosed on the basis of spirometry in the Department of Pulmonary Medicine, Era’s Lucknow Medical College & Hospital (ELMC&H). Patients were received Fluticasone/Formoterol (200/10 μg OD). The drugs were administered through metered-dose inhaler (MDI).
Results: The mean forced expiratory volume recorded before treatment 54.92±4.47 in a group who were treated with formoterol/fluticasone combination changed to 75.48±5.03 after the treatment. No significant adverse effect of this regimens was observed.
Conclusions: The results of this study revealed this regimen showed a significant improvement in lung functions without any significant adverse event.
The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lanc. 1998;351:1225-32.
Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, et al. ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. The Lanc. 2006;368(9537):733-43.
Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allerg. 2004;59(5):469-78.
Alderson M. Trends in morbidity and mortality from asthma. Populat Tren. 1987;49:18-2.
Aggarwal AN, Chaudhry K, Chhabra SK, D Souza GA, Gupta D, Jindal SK, et al. Prevalence and risk factors for bronchial asthma in Indian adults: a multicentre study. Ind J Che Disea Alli Scienc. 2006;48(1):13.
European Community Respiratory Health Survey. Variations in the prevalence of respiratory symptoms,selfreported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J. 1996;9:687-95.
Burney P, Malmberg E, Chinn S, Jarvis D, Luczynska C, Lal E. The distribution of total and specific serum IgE in the European Community Respiratory Health Survey. J Allergy Clin Immunol. 1997;99:314-22.
Jindal SK, Gupta D, Aggarwal AN, Agarwal R; World Health Organization; Government of India.Guidelines for the management of asthma at the primary and secondary levels of health care in India. Indian J Chest Dis Allied Sci. 2005;47:309-43.
Tamm M, Richards DH, Beghé B, Fabbri L. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice. Respirat Medici. 2012;106:S9-19.
GINA (Global Initiative for Asthma). GINA report: Global Strategy for Asthma Management and Prevention, 2007.
Harold SN. â-Adrenergic bronchodilators. N Engl J Med. 1995;33:499-505.
Barnes PJ. New drugs for asthma. Clin Exp Aller. 1996;26:735-45.
Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci. 1993;52:2145-60.
Pearlman DS, LaForce CF, Kaiser K. Fluticasone/Formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma. Clin Ther. 2013;35(7):950-66.